Search over 3,000 reports

    Endometriosis- Pipeline Insights, 2017

    Endometriosis- Pipeline Insights, 2017
    Date: Nov, 2017
    Type: Pharmaceutical Industry Report
    Pages: 108
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIPI0148
    DelveInsight's, "Endometriosis-Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Endometriosis. This report provides information on the therapeutic development based on the Endometriosis dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the company's information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. The report covers 30+ drugs.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
    Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
    Introduction
    Overview
    Pipeline Therapeutics
    Therapeutics under Development by Companies
    Last Stage Products (Phase III)
    Mid Stage Products (Phase II)
    Early Stage Products (Phase I)
    Pre-clinical Stage Products
    Therapeutic Assessment
    Dormant Products
    Discontinued Products
    Companies Involved in Therapeutics Development
    Appendix
    DelveInsight Consulting Services
    About DelveInsight
    Contact Us
    Disclaimer
    Table 1:Number of Products Under Development for Endometriosis
    Table 2: Number of Products under Development by Companies
    Table 3: Last Stage Products (Phase II)
    Table 4: Mid Stage Products (Phase II)
    Table 5: Early Stage Products (Phase I)
    Table 6: Pre-Clinical Stage Products
    Table 7: Assessment by Monotherapy Products
    Table 8: Assessment by Route Of Administration
    Table 9:Assessment by Stage and Route Of Administration
    Table 10: Assessment by Molecule Type
    Table 11: Assessment by Stage and Molecule Type
    Table 12:Dormant Products
    Table 13: Discontinued Products
    Table 14: AbbVie , Overview
    Table 15: Addex Therapeutics, Overview
    Table 16:Astellas, Overview
    Table 17:Bayer , Overview
    Table 18: Endoceutics , Overview
    Table Continued???
    Table 32:Takeda Pharmaceuticals , Overview
    Table 33:ValiRx, Overview
    Figure 1: Endometriosis
    Figure 2: Stages of Endometriosis
    Figure 3: Number of Products under Development for Endometriosis
    Figure 4: Last Stage Products (Phase II)
    Figure 5: Mid Stage Products (Phase II)
    Figure 6: Early Stage Products (Phase I )
    Figure 7: Pre-Clinical Stage Products
    Figure 8: Assessment by Monotherapy Products
    Figure 9: Assessment by Route of Administration
    Figure 10: Assessment by Stage and Route of Administration
    Figure 11: Assessment by Molecule Type
    Figure 12: Assessment by Stage and Molecule Type
    Figure 13: Dormant Products
    Figure 14:Discontinued Products
    Endometriosis Pipeline Drugs

    Endometriosis Pipeline Assessment

    Endometriosis Pipeline Analysis

    Endometriosis Drugs under Development

    Endometriosis Discovery drugs

    Endometriosis Preclinical drugs

    Endometriosis Phase I drugs

    Endometriosis Phase II drugs

    Endometriosis Phase III Pipeline Drugs Assessment

    Endometriosis Preregistration drugs

    Endometriosis Molecules in pipeline

    • Single User License
      (20% Off)
      $1,500.00
      $1200
    • Site License
      (30% Off)
      $3,000.00
      $2100
    • Global License
      (40% Off)
      $4,500.00
      $2700

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap